Exosome-delivered microRNAs modulate the inflammatory response to endotoxin

Margaret Alexander, Ruozhen Hu, Marah C Runtsch, Dominique A Kagele, Timothy L Mosbruger, Tanya Tolmachova, Miguel C Seabra, June L Round, Diane M Ward, Ryan M O'Connell, Margaret Alexander, Ruozhen Hu, Marah C Runtsch, Dominique A Kagele, Timothy L Mosbruger, Tanya Tolmachova, Miguel C Seabra, June L Round, Diane M Ward, Ryan M O'Connell

Abstract

MicroRNAs regulate gene expression posttranscriptionally and function within the cells in which they are transcribed. However, recent evidence suggests that microRNAs can be transferred between cells and mediate target gene repression. We find that endogenous miR-155 and miR-146a, two critical microRNAs that regulate inflammation, are released from dendritic cells within exosomes and are subsequently taken up by recipient dendritic cells. Following uptake, exogenous microRNAs mediate target gene repression and can reprogramme the cellular response to endotoxin, where exosome-delivered miR-155 enhances while miR-146a reduces inflammatory gene expression. We also find that miR-155 and miR-146a are present in exosomes and pass between immune cells in vivo, as well as demonstrate that exosomal miR-146a inhibits while miR-155 promotes endotoxin-induced inflammation in mice. Together, our findings provide strong evidence that endogenous microRNAs undergo a functional transfer between immune cells and constitute a mechanism of regulating the inflammatory response.

Figures

Figure 1. miR-155 is transferred between BMDCs…
Figure 1. miR-155 is transferred between BMDCs and is present in exosomes.
(a) A schematic of the co-culture experiment. (b) Representative FACS plots where co-cultured CD45.1+Wt and CD45.2+miR-155−/− CD11c+ BMDCs were separated (n=4). (c) Relative miR-155 levels were quantified via qRT–PCR from isolated miR-155−/− BMDCs that had been cultured alone or with Wt BMDCs in the presence or the absence of LPS for 24 h (n=4). (d) Relative miR-155 levels were measured via qRT–PCR in miR-155−/− BMDCs either cultured alone or with Wt BMDCs separated by a 0.4-μm filter for 24 h with or without LPS (n=3). (e) Cryo-EM of exosomes isolated from Wt BMDCs. Scale bar, 200 nm. Red box is enlarged in the upper left corner. (f) CD63 protein levels in the exosomal pellet from Wt and miR-155−/− BMDCs treated with or without LPS. (g) Relative levels of miR-155 in exosomes derived from Wt or miR-155−/− BMDCs treated with or without LPS (n=3). (h) Exosome quantification of Wt BMDCs treated with or without GW4869 (n=3). Limit of detection is 2 × 107 exosomes. (i) Relative levels of miR-155 were measured in the exosomal pellet from Wt BMDCs treated with or without LPS and GW4869 as quantified by qRT–PCR (n=2). (j) Exosome quantification of Wt and Rab27 DKO BMDC-derived exosomes (n=2). Limit of detection is 2 × 107 exosomes. (k) miR-155 levels in exosome pellets from Wt and Rab27 DKO BMDC-conditioned medium (n=2). Data represent two independent experiments and are presented as the mean±s.d. (error bars). *P<0.05; **P<0.01, Student's t-test.
Figure 2. Functional transfer of miR-155 via…
Figure 2. Functional transfer of miR-155 via exosomes in vitro.
(a) Schematic of the exosome transfer experiment. (b) qRT–PCR was used to measure relative miR-155 levels in miR-155−/− BMDCs that received either Wt or miR-155−/− exosomes derived from BMDCs treated with or without GW4869 (n=5). (c,d) mRNA levels of miR-155 targets, BACH1 and SHIP1, from the same experiment shown in b as measured by qRT–PCR (n=5). (e) Representative western blottings of SHIP1 and β-actin in miR-155−/− BMDCs given either Wt or miR-155−/− exosomes. (f) Protein levels of SHIP1 were quantified using ImageJ software (n=2). (g) Relative miR-155 levels in Wt BMDCs given either Wt or miR-155−/− exosomes as quantified by qRT–PCR (n=6). (h,i) BACH1 and SHIP1 mRNA levels were measured in the same experiment shown in g as quantified by qRT–PCR (n=6). (j) qRT–PCR was used to quantify HO1 mRNA levels during the experiment in b (n=5). (k) Western blotting for AGO2 and β-actin from miR-155−/− BMDCs given Wt or miR-155−/− exosomes. On the left is the input (whole-cell lysate), the middle is from the pan-AGO pulldown where one-third of input was used and the right is the IgG pulldown where one-third of the input was used. (l) Relative miR-155 levels were quantified via qRT–PCR in the same experiment shown in k. (m) miR-146a levels were quantified using qRT–PCR during the experiment in k. Levels in l,m are plotted as Ago:IgG. Dotted line separates input from pull-down groups. Data represent two independent experiments and are presented as the mean±s.d. (error bars). *P<0.05; **P<0.01, Student's t-test.
Figure 3. Functional transfer of miR-146a via…
Figure 3. Functional transfer of miR-146a via exosomes in vitro.
(a) Levels of miR-146a in the exosomal pellet derived from BMDCs that were treated with or without GW4869 and LPS (n=2). (b) miR-146a levels in Wt and Rab27 DKO BMDC-derived exosomal pellets (n=2). (c) Schematic of miR-146a exosome-transfer experiment where Wt or miR-146a−/− exosomes were isolated from BMDCs and transferred to recipient miR-146a−/− BMDCs. RNA was isolated after 24 h and the presence of miR-146a was assayed via qRT–PCR. (d) Relative levels of miR-146a in miR-146a−/− BMDCs given exosomes derived from Wt or miR-146a−/− BMDCs (n=4). (e) mRNA levels of miR-146a target, IRAK1, were measured from the same cells as in d via qRT–PCR (n=4). (f) Representative western blottings of IRAK1 and β-actin from miR-146a−/− cells given either Wt or miR-146a−/− exosomes. (g) IRAK1 protein levels were quantified using ImageJ software (n=2). (h) mRNA levels of miR-146a target, TRAF6, were measured in the same cells as in d via qRT–PCR. (i) Western blottings for TRAF6 and β-actin from miR-146a−/− BMDCs given either Wt or miR-146a−/− exosomes (n=2). (j) Western blotting results are quantified with ImageJ software. (k) Copy number of miR-146a in Wt and miR-146a−/− exosomes (n=3). Copy number is calculated based on a standard curve where a known amount of synthetic miR-146a was spiked into miR-146a−/− BMDC-derived exosome pellet followed by RNA isolation and qRT–PCR. (l) Copy number of miR-146a was measured via qRT–PCR in miR-146a−/− recipient BMDCs that received either Wt or miR-146a−/− exosomes (146a−/− BMDC+Wt exos and 146a−/− BMDC+146a−/− exos), as well as in Wt and miR-146a−/− donor BMDCs (n=3). Average copy number is displayed above. Copy number is calculated based on a standard curve where a known amount of synthetic miR-146a was spiked into miR-146a−/− BMDC pellet followed by RNA isolation and qRT–PCR. Data represent two independent experiments and are presented as the mean±s.d. (error bars). *P<0.05, Student's t-test.
Figure 4. Seed-dependent repression of miRNA targets…
Figure 4. Seed-dependent repression of miRNA targets by exosome-delivered miR-155 and miR-146a.
(a) Schematic for mimic experiment. (b,c) Relative mRNA levels of the miR-155 targets SHIP1 and BACH1 were measured via qRT–PCR in recipient cells that received exosomes with no mimics (No) (n=7), miR-155 seed mutant mimics (Seed) (n=4), with scrambled mimics (Scram) (n=3), or with miR-155-mimics (Mimic) (n=7). (d,e) qRT–PCR was preformed to assay the mRNA levels of the miR-146a targets, IRAK1 and TRAF6, following treatment with exosomes containing miR-146a mimics and controls as in b,c. Results are reported normalized to exosomes with no mimics added, which is set as 1. (f) Protein levels of TRAF6, IRAK1 and β-actin were determined via western blotting using lysates from miR-146a−/− BMDCs that received exosomes containing no mimics, seed mutant mimics or Wt mimics. Numbers below the blot represent relative protein levels with no mimics set as 1 following normalization to β-actin. (g) Schematic for 3′-UTR luciferase reporter assays in h,i. (h) Results from 3′-UTR luciferase reporter assays where miR-155−/− BMDCs were transfected with a pmiReport control vector, a BACH1 3′-UTR vector (BACH1), a BACH1 miR-155-binding site (bs) mutant vector (BACH1 mutant), or a 2mer-positive control vector. Transfected BMDCs were treated 6 h later with or without Wt exosomes and per cent change in luciferase activity of exosome treated BMDCs compared with no exosome treatment was calculated after 24 h (n=4). (i) Results from 3′-UTR luciferase reporter assay where miR-146a−/− BMDCs were transfected with a pmiReport control vector, a TRAF6 3′-UTR vector (TRAF6) or TRAF6 miR-146a bs mutant vector (TRAF6 mutant). Six hours later, the BMDCs were treated with or without Wt exosomes and per cent repression of luciferase activity was calculated 24 h after exosome transfer (n=4). Results represent two independent experiments. All data are presented as the mean±s.d. (error bars). *P<0.05; **P<0.01, ****P<0.0001; Student's t-test.
Figure 5. Exosomal transfer of miR-155 and…
Figure 5. Exosomal transfer of miR-155 and miR-146a programme the response to LPS in vitro
(a) A schematic of the experimental design for b. (b) Exosomes were isolated from Wt or miR-155−/− BMDCs and given to miR-155−/− BMDCs for 24 h. Cells were then treated with or without LPS and media was taken after 6 h for an IL-6 enzyme-linked immunosorbent assay. Relative IL-6 protein levels are shown (n=4). (c) Schematic for experiments in df. (df) qRT–PCR was used to quantify mRNA levels of IL-10, IL-6 and IL-12 p40 in miR-146a−/− BMDCs given exosomes from Wt or miR-146a−/− BMDCs for 24 h followed by stimulation with or without LPS for 6 h (n=4). Data represent two independent experiments. All data are presented as the mean±s.d. (error bars). *P<0.05; Student's t-test.
Figure 6. Transfer of endogenous miR-155 between…
Figure 6. Transfer of endogenous miR-155 between haematopoietic cells in vivo.
(a) CD63 western blotting using exosomes isolated directly from the BM of Wt or miR-155−/− mice. 1 and 2 stand for two biological replicates. (b,c) Levels of miR-155 and miR-146a in exosomes isolated form Wt and miR-155−/− mouse BM as measured by qRT–PCR (n=2). (d) Schematic of the in-vivo experiment. (e) qRT–PCR was used to quantify levels of miR-155 in miR-155−/− CD45.2+ BM cells that were B220+, CD3+, or CD11b+ from miR-155−/− mice that were either reconstituted with Wt (CD45.1+) and miR-155−/− BM, or miR-155−/− BM alone as indicated (n=5). (fh) Representative FACS plots of the cell types in isolated BM shown in e (n=5). (ik) miR-155−/− mice were i.p. injected multiple times over a week with either Wt or miR-155−/− exosomes. CD3+ T cells, B220+ B cells and CD11b+ myeloid cells were sorted from mouse spleens and qRT–PCR was preformed to analyse the delivery of miR-155 to each cell type (n=5). All data are presented as the mean±s.d. (error bars). *P<0.05; **P<0.01, ***P<0.001, Student's t-test.
Figure 7. miR-155-containing exosomes promote a heightened…
Figure 7. miR-155-containing exosomes promote a heightened response to LPS in miR-155−/− mice.
(a) Schematic of the experimental design where miR-155−/− mice were i.p. injected with either Wt or miR-155−/− BMDC-derived exosomes and then challenged with LPS 24 h later. Blood was taken 2 h post LPS injection and the spleen, liver and BM were harvested 24 h post injection. (b,c) Serum TNFα and IL-6 concentrations were analysed via enzyme-linked immunosorbent assay 2 h after injection of LPS in miR-155−/− mice that had been pretreated with either Wt or miR-155−/− exosomes (n=5). (df) qRT–PCR was preformed using RNA isolated from the spleen, liver and BM, to assay the relative levels of exosomally delivered miR-155 (n=5). (gi) mRNA levels of the miR-155 targets SHIP1 and BACH1 were measured in the spleen, liver and/or the BM using qRT–PCR (n=5). All data are presented as the mean±s.d. (error bars). *P<0.05; **P<0.01, Student's t-test.
Figure 8. miR-146a-containing exosomes reduce inflammatory responses…
Figure 8. miR-146a-containing exosomes reduce inflammatory responses to LPS in miR-146a−/− mice.
(a) Schematic of the experimental design where miR-146a−/− mice were i.p. injected with either Wt or miR-146a−/− BMDC-derived exosomes and then challenged with LPS 24 h later. Blood was taken 2 h post LPS injection and the spleen, liver and BM were harvested 24 h post injection. (b,c) Serum TNFα and IL-6 were analysed via enzyme-linked immunosorbent assay 2 h after injection of LPS (n=5). (df) qRT–PCR was preformed using RNA isolated from the spleen, liver and BM, to assay the relative levels of exosomally delivered miR-146a (n=5). (gi) mRNA levels of the miR-146a targets TRAF6 and IRAK1 were measured in the spleen, liver and/or the BM using qRT–PCR (n=5). All data are presented as the mean±s.d. (error bars). *P<0.05; **P<0.01, Student's t-test.
Figure 9. miR-146a-containing exosomes reduce inflammatory response…
Figure 9. miR-146a-containing exosomes reduce inflammatory response to LPS in Wt mice.
(a) Schematic of the experimental design where Wt mice were i.p. injected with either Wt or miR-146a−/− BMDC-derived exosomes and then challenged with LPS 24 h later. Blood was taken 2 h post LPS injection and the spleen, liver and BM were harvested 24 h post injection. (b,c) Serum TNFα and IL-6 were analysed via enzyme-linked immunosorbent assay 2 h after injection of LPS (n=5). (df) qRT–PCR using RNA isolated from the spleen, liver and BM was performed to assay the relative levels of exosomally delivered miR-146a (n=5). (gi) mRNA levels of the miR-146a targets TRAF6 and IRAK1 were measured in the spleen, liver and/or the BM using qRT–PCR (n=5). Results represent two independent experiments. All data are presented as the mean±s.d. (error bars). *P<0.05; ****P<0.0001, Student's t-test.

References

    1. Tian T., Wang Y., Wang H., Zhu Z. & Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. J. Cell. Biochem. 111, 488–496 (2010) .
    1. Raposo G. & Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200, 373–383 (2013) .
    1. Théry C., Zitvogel L. & Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569–579 (2002) .
    1. Valadi H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659 (2007) .
    1. Zhou W. et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25, 501–515 (2014) .
    1. Bang C. et al. Cardiac fibroblast—derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 124, 2136–2146 (2014) .
    1. Aucher A., Rudnicka D. & Davis D. M. MicroRNAs transfer from human macrophages to hepato-carcinoma cells and inhibit proliferation. J. Immunol. 191, 6250–6260 (2013) .
    1. Zhang Y. et al. Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. Mol. Cell 288, 23586–23596 (2010) .
    1. Chairoungdua A., Smith D. L., Pochard P., Hull M. & Caplan M. J. Exosome release of β-catenin: a novel mechanism that antagonizes Wnt signaling. J. Cell Biol. 190, 1079–1091 (2010) .
    1. Sheldon H. et al. New mechanism for Notch signaling to endothelium at a distance by delta-like 4 incorporation into exosomes. Blood 116, 2385–2394 (2010) .
    1. Raposo G. et al. B Lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183, 1161–1172 (1996) .
    1. Montecalvo A. et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119, 756–766 (2012) .
    1. Kosaka N. et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 285, 17442–17452 (2010) .
    1. Mittelbrunn M. et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2, 282 (2011) .
    1. Chen X., Liang H., Zhang J., Zen K. & Zhang C.-Y. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell 3, 28–37 (2012) .
    1. Villarroya-Beltri C. et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun. 4, 2980 (2013) .
    1. Koppers-Lalic D. et al. Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes. Cell Rep. 8, 1649–1658 (2014) .
    1. Squadrito M. L. et al. Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. Cell Rep. 8, 1432–1446 (2014) .
    1. Villarroya-Beltri C., Baixauli F., Gutiérrez-Vázquez C., Sánchez-Madrid F. & Mittelbrunn M. Sorting it out: regulation of exosome loading. Semin. Cancer Biol. 28, 3–13 (2014) .
    1. Gibbings D. J., Ciaudo C., Erhardt M. & Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat. Cell Biol. 11, 1143–1149 (2009) .
    1. Guduric-Fuchs J. et al. Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genomics 13, 357 (2012) .
    1. Katakowski M., Buller B., Wang X., Rogers T. & Chopp M. Functional microRNA is transferred between glioma cells. Cancer Res. 70, 8259–8263 (2010) .
    1. Okoye I. S. et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 41, 89–103 (2014) .
    1. Pegtel D. M. et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl Acad. Sci. USA 107, 6328–6333 (2010) .
    1. Huffaker T. B. et al. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep. 2, 1697–1709 (2012) .
    1. Boldin M. P. et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J. Exp. Med. 208, 1189–1201 (2011) .
    1. Turner M. L., Schnorfeil F. M. & Brocker T. MicroRNAs regulate dendritic cell differentiation and function. J. Immunol. 187, 3911–3917 (2011) .
    1. O'Connell R. M., Taganov K. D., Boldin M. P., Cheng G. & Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl Acad. Sci. USA 104, 1604–1609 (2007) .
    1. O'Connell R. M. et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp. Med. 205, 585–594 (2008) .
    1. Taylor D. D. & Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110, 13–21 (2008) .
    1. Hu R. et al. miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation. Immunity 41, 605–619 (2014) .
    1. Mullokandov G. et al. High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat. Methods 9, 840–846 (2013) .
    1. Kurowska-Stolarska M. et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc. Natl Acad. Sci. USA 108, 11193–11198 (2011) .
    1. Tili E. et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNFa stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 179, 5082–5089 (2007) .
    1. Chevillet J. R. et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc. Natl Acad. Sci. USA 111, 14888–14893 (2014) .
    1. Mo M.-H., Chen L., Fu Y., Wang W. & Fu S. W. Cell-free circulating miRNA biomarkers in cancer. J. Cancer 3, 432–448 (2012) .
    1. Kosaka N., Iguchi H. & Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101, 2087–2092 (2010) .
    1. Etheridge A., Lee I., Hood L., Galas D. & Wang K. Extracellular microRNA: a new source of biomarkers. Mutat. Res. 717, 85–90 (2011) .
    1. Kim S. H. et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol. Ther. 13, 289–300 (2006) .
    1. Bhatnagar S., Shinagawa K., Castellino F. J. & Schorey J. S. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 110, 3234–3244 (2007) .
    1. Lai R. C., Chen T. S. & Lim S. K. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen. Med. 6, 481–492 (2011) .
    1. Ohno S. et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21, 185–191 (2013) .
    1. Hu G., Drescher K. M. & Chen X.-M. Exosomal miRNAs: biological properties and therapeutic potential. Front. Genet. 3, 56 (2012) .
    1. Yang M. et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 10, 117 (2011) .
    1. Taganov K. D., Boldin M. P., Chang K. & Baltimore D. NF-kB-dependent induction of miR-146a, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl Acad. Sci. USA 103, 12481–12486 (2006) .
    1. Théry C., Clayton A., Amigorena S. & Raposo G. Isolation and characterization of exosomes from cell culture supernatants. Curr. Protoc. Cell Biol. doi:10.1002/0471143030.cb0322s30 (2006) .

Source: PubMed

3
Tilaa